Introduction {#S1}
============

Mutations in leucine-rich repeat kinase 2 (*LRRK2*) gene cause late-onset, autosomal-dominant forms of Parkinson's disease (PD) ([@B74]; [@B107]). To date, at least seven missense mutations (N1437H, R1441C/G/H, Y1699C, G2019S, I2020T) have been identified as definitely causal, and G2019S is the most frequent mutation among them. The pathology of PD is characterized by the loss of midbrain dopaminergic neurons as well as the formation of Lewy bodies, the cytoplasmic inclusion composed primarily of α-synuclein filaments. Importantly, a majority of familial PD patients harboring LRRK2 mutation display an accumulation of Lewy bodies in affected brain lesions, although a range of heterogeneity (i.e., some cases are Lewy body predominant, while others exhibit tau deposits or lack specific intraneuronal inclusions) characterizes the neuropathology of LRRK2 mutant PD ([@B49]; [@B48]). The link of LRRK2 to sporadic PD has also been suggested by a set of genome-wide association studies (GWAS) where common variants around *LRRK2* gene have been identified as a risk factor of PD ([@B85]; [@B89]; [@B55]). In addition, activation of LRRK2 kinase has been implicated in sporadic PD and non-LRRK2 PD models ([@B20]), placing LRRK2 in more common pathway for PD manifestation. Thus, elucidating the role of LRRK2 in pathological as well as physiological situations may provide hints for the establishment of rational strategy to treat PD.

In addition to PD, previous GWAS have also identified *LRRK2* in a susceptible locus for Crohn's disease ([@B5]) and leprosy ([@B102]), both of which are immune-related disorders. Some functional variants in *LRRK2* gene influencing the disease risk are shared between Crohn's disease and PD ([@B43]). Another study has also pointed to a genetic association between LRRK2 and susceptibility to systemic lupus erythematosus (SLE) ([@B104]). Consistently, LRRK2 is considered to be involved in a wide range of disorders affecting both brain and periphery.

LRRK2 is a multidomain protein kinase harboring several characteristic domains, such as ankyrin repeats, LRR (leucine-rich repeat), ROC (Ras of complex), COR (*C*-terminal of ROC), WD40 and kinase domains. Due to the presence of a tandem ROC-COR domain, LRRK2 is classified as a member of the ROCO protein family ([@B12]). LRRK2 expression is detected in a broad range of organs and tissues including brain, and is especially high in kidney, lung and spleen ([@B9]; [@B54]; [@B63]) as well as in immune cells ([@B29]; [@B63]). In the central nervous system, LRRK2 is expressed in a subset of neurons including those in the substantia nigra ([@B8]; [@B35]), but is reported to be more highly expressed in astrocytes and microglia ([@B37]). In immune cells, LRRK2 expression is especially high in macrophages, B cells and neutrophils ([@B9]; [@B54]; [@B29]; [@B63]; [@B25]). A noteworthy finding is that the expression of LRRK2 in macrophages is potently induced by IFN-γ stimulation ([@B29]). These expression patterns point to variable roles of LRRK2, such as immune-related functions.

Within cells, LRRK2 is known to be predominantly distributed throughout the cytoplasm ([@B100]), whereas biochemical fractionation studies have shown that at least a portion is associated with membranes, suggesting the localization to specific organelles or membrane microdomains ([@B35]; [@B7]; [@B87]). However, immunocytochemical or ultrastructural analyses have not provided consistent results for the LRRK2 localization; the possible subcellular locations include Golgi, mitochondria, endosomes, lysosomes, endoplasmic reticulum (ER), multivesicular bodies, amphisomes and autolysosomes ([@B8]; [@B35]; [@B2]; [@B97]). We have detected the endogenous LRRK2 on a portion of enlarged lysosomes, which was observed in ∼0.1-1% of total healthy cells or in a majority of cells treated with chloroquine, by using three well-characterized antibodies ([@B24]). In any event, the following issues should be taken into account when interpreting the localization studies; first, overexpressed proteins often display non-physiological localization patters, and indeed LRRK2 tends to form aggregate- or skein-like structures in cells when overexpressed in cultured cells. Another issue is that, even when endogenous LRRK2 are analyzed by specific antibodies, their properties on immunocytochemical analyses are not necessarily defined. The endolysosomal localization of LRRK2 will be specifically discussed later in this article.

Endolysosomal system, especially lysosomes, has attracted much attention in the field of LRRK2 research, given the accumulating evidence that knocking out LRRK2 or introduction of pathogenic mutations causes lysosomal abnormalities in animals and cultured cells. In addition, dysregulation of endolysosomal system has been implicated more broadly in familial and sporadic PD other than LRRK2-related PD. For instance, the lysosomal enzyme glucocerebrosidase (GBA) and the lysosomal K^+^ channel TMEM175 are well-validated risk factors identified by GWAS of sporadic PD ([@B70]; [@B13]; [@B10]; [@B46]). Also, the lysosomal *P*-type ATPase ATP13A2 (PARK9) and the retromer complex component VPS35 (PARK17) regulating endosome-to-Golgi transport are the products of the causative genes for familial PD or related diseases ([@B80]; [@B96]; [@B106]). The endolysosomes are further considered to play an important role in the aggregation or propagation of α-synuclein deposited in PD brains.

As the kinase activity of LRRK2 has been shown to be responsible for most of its functions in endolysosomes and other systems, a deeper understanding of the downstream of LRRK2 kinase activity is critical. The substrates of LRRK2 in cells have long been enigmatic until the identification of a set of Rab GTPases ([@B91]). Small Rab GTPases are the key regulators of intracellular vesicle trafficking, constituting the largest family in the Ras-related small GTPase superfamily. More than 60 different Rabs have been identified in humans, but it is noteworthy that the substrates of LRRK2 are limited to a small proportion, *e.g.*, Rab8 and Rab10 ([@B91], [@B90]). The importance of this phosphorylation is particularly highlighted by the finding that LRRK2 pathogenic mutations commonly augment its activity to phosphorylate these Rab GTPases. Thus, elucidating the role and significance of Rab phosphorylation is vital to understand the pathways leading to PD as well as the basic biology of LRRK2, including those in endolysosomes. In this article, we aim to summarize our current understanding about the relationship among LRRK2, Rab, and endolysosomal system, and discuss the possible involvement of the dysregulation of this system in the pathomechanism of PD.

The Role of LRRK2 in Lysosomal Homeostasis {#S2}
==========================================

Lysosomes are membrane-enclosed organelles that play essential roles in many cellular processes including cell growth, division and differentiation ([@B78]; [@B53]), whereas they have classically been established as terminal digestive system degrading materials from both inside and outside of the cells ([@B16]). Lysosomes contain a series of acid-dependent hydrolases as well as highly glycosylated integral membrane proteins. Similar properties are shared with a set of cell type-specific compartments called "lysosome-related organelles," such as melanosomes and lung lamellar bodies ([@B17]). The relationship between lysosome and LRRK2 has been particularly highlighted over the past years, since a number of studies have reported the lysosomal pathology in *Lrrk2* knockout (KO) animals, such as age-dependent accumulation of autofluorescent lipofuscin granules that are composed of undigested materials derived from lysosomes ([@B94], [@B93]; [@B38]; [@B40]; [@B4]; [@B71]; [@B11]; [@B27]; [@B52]). Indeed, detailed histopathological analyses have demonstrated a marked enlargement of lysosomes or lysosome-related organelles (called lamellar bodies) in the kidney or lung of *Lrrk2* KO rodents ([@B38]; [@B4]; [@B27]). Treatment with LRRK2 kinase inhibitors of non-human primates also induced abnormal cytoplasmic accumulation of lamellar bodies in type II pneumocytes of the lung ([@B27]). Thus, there is little doubt that the physiological function of LRRK2 is related to the maintenance of lysosomal morphology or functions.

The close relationship between LRRK2 and lysosomes has already been described earlier in LRRK2 research. For example, neurons overexpressing pathogenic mutant LRRK2 accumulate phospho-tau-positive lysosomal inclusions ([@B59]), and LRRK2 is localized to membranous and vesicular structures, including lysosomes and endosomes, in mammalian brains ([@B8]). Later on, the lysosomal regulation by LRRK2 have been increasingly described using various cellular systems and model organisms. In Drosophila, an ortholog of LRRK2 (Lrrk) localizes to the endolysosomal membranes and negatively regulates Rab7-dependent perinuclear localization of lysosomes ([@B23]). In addition, Lrrk loss-of-function flies display the accumulation of markedly enlarged lysosomes that are laden with undigested contents ([@B22]). In mouse primary astrocytes, overexpressed LRRK2 localizes primarily to lysosomes and regulates the size of lysosomes through its kinase activity ([@B37]). Mouse primary neurons harboring LRRK2 G2019S mutation also display altered lysosomal morphology, such as the reduction of lysosomal size and the increase in the number and total area of lysosomes ([@B86]). In our hands, endogenous LRRK2 in mammalian cells negatively regulated the enlargement of overloaded lysosomes ([@B24]), consistent with the above studies. In relation to PD, the disruption of lysosomal morphology was observed in fibroblasts from PD patients harboring the G2019S mutation ([@B41]).

The reported effects of LRRK2 on lysosomal morphology *in vivo* or in cultured cells are summarized in [Table 1](#T1){ref-type="table"}. Knocking out LRRK2 caused lysosomal enlargement in most experiments, whereas the effect of pathogenic mutant LRRK2 (*e.g.*, G2019S) on lysosome size and number is not consistent among studies, which may be due to a variety of experimental conditions including differences in cells/tissues or methods of gene manipulations (overexpression, knockin, etc.). Nonetheless, these studies consistently showed that the effects on lysosomes by LRRK2 is dependent on its kinase activity. Taken together, these studies suggest that LRRK2 kinase plays a pivotal role in the regulation or maintenance of lysosomal homeostasis.

###### 

Representative studies on the effect of LRRK2 onlysosome morphology.

  References   Cells, tissues                 Manipulation                               Effects on lysosome morphology
  ------------ ------------------------------ ------------------------------------------ ----------------------------------------------------------------------------------------------------------------------------
  [@B38]       mouse kidney, lung             knockout                                   Increase in size and number of lysosomes in mouse KO kidney proximal tubules and lamellar bodies in KO lung type II cells.
  [@B4]        rat kidney, lung               knockout                                   Increase in size and number of lysosomes in rat KO kidney proximal tubules and lamellar bodies in KO lung type II cells.
  [@B22]       Drosophila                     knockout                                   Enlarged lysosomes with undigested contents in lrrk null flies
  [@B27]       monkey lung                    inhibitor dosing                           Increase in size and number of lamellar bodies in the lung of monkey dosed with LRRK2 kinase inhibitors
  [@B37]       Primary mouse astrocytes       overexpression of WT or G2019S, knockout   Lysosomes were enlarged, the number was decreased upon G2019S overexpression. Increase in number in KO cells.
  [@B41]       G2019S patient fibroblast      endogenous G2019S mutation                 Enlarged and clustered lysosomes in LRRK2-PD fibroblasts
  [@B86]       Primary mouse neurons          G2019S knockin                             Lysosome size was decreased, the number and total area were increased in G2019S neurons.
  [@B24]       RAW264.7 cells, HEK293 cells   knockdown, overexpression                  Knockdown caused the enlargement upon overload stress. Overexpression, especially PD mutants, suppressed the enlargement.

LRRK2, Endolysosomal Trafficking and Autophagy {#S3}
==============================================

Substances destined for degradation are transported into lysosomes mostly through two distinct processes: the endocytosis of extracellular materials and autophagy of intracellular components. These two processes are dynamically regulated by membrane transport ([@B84]), and LRRK2 has been implicated in both processes. Regarding the endocytosis pathway, [@B32] have shown that the overexpression of pathogenic mutant LRRK2 delays endosomal trafficking of the epidermal growth factor receptor (EGFR) by decreasing Rab7 activity-mediated late endosomal budding. Additionally, their recent study has shown that LRRK2-mediated inhibition of Rab8a also is involved in this impaired EGFR trafficking by interfering its recycling ([@B82]).

The affected cargoes are not likely restricted to EGFR, as it has been demonstrated that LRRK2 controls the vesicular endosomal trafficking of major lysosomal membrane proteins (LMPs), such as LAMP1, LAMP2, or LIMP2, to lysosomes through regulation of the adaptor protein complex 3 (AP-3) ([@B52]). Actually, LRRK2 can bind β3A subunit of the AP-3 complex, and genetic interaction between the orthologs of LRRK2 and AP-3 was revealed in *Caenorhabditis elegans* in terms of the regulation of axon termination. Of note, the endosomal trafficking of LIMP2, a cargo of AP-3 complex, may be particularly important in relation to the pathomechanism of PD, given that LIMP2 is selectively responsible for the intracellular transport of a lysosomal enzyme β-glucocerebrosidase (βGC), a major risk factor for developing PD, to lysosomes through direct binding ([@B81]; [@B84]), and that LIMP2 deficiency in mice leads to α-synuclein accumulation as well as the reduction of lysosomal βGC activity ([@B83]). Also, *SCARB2* gene that encodes LIMP2 has been identified at a PD risk locus ([@B21]; [@B68]; [@B42]), and the recent study of age at onset of PD GWAS that is largest to date has confirmed *SCARB2* as a risk gene ([@B10]).

In addition to endocytic pathway, LRRK2 appears to modulate other lytic pathways, such as phagocytosis and autophagy. Regarding phagocytosis, it has been shown that LRRK2 regulates the phagocytic activity in myeloid cells via WAVE2 complex, an actin-cytoskeletal regulator ([@B50]). Another study has reported that LRRK2 negatively regulates phagosome maturation in macrophages via the recruitment of the Class III phosphatidylinositol-3 kinase (PI3K) complex and Rubicon to the phagosomes ([@B34]). Although both studies clearly showed the involvement of LRRK2 kinase activity, its role in phagocytosis appears to be different; whereas LRRK2 activity facilitates the step of engulfment, it also suppresses phagosomal maturation at a later step.

Regarding autophagy (especially macroautophagy), a lysosome-mediated process of cytoplasmic degradation, a growing number of studies have suggested the involvement of LRRK2. *Lrrk2* KO mice exhibit alterations in the levels of LC3-II and p62, a reliable autophagy marker and an autophagy substrate, respectively ([@B94], [@B93]). *In vitro* studies have shown that the overexpression of G2019S LRRK2 in SH-SY5Y cells caused a marked increase in the LC3-positive autophagic vacuoles ([@B77]), and the expression of LRRK2 in HEK293 cells also caused a similar increase in autophagosome formation ([@B31]). Knockdown of LRRK2 in cells stably expressing fluorescence-tagged LRRK2 increased autophagic activity and prevented the starvation-induced cell death ([@B2]), and the pharmacological inhibition of LRRK2 kinase activity similarly stimulated macroautophagy ([@B64]). In contrast, another study showed that knockdown of endogenous LRRK2 in macrophage or microglial cells decreased LC3-II levels and autophagy flux ([@B87]). Thus, it is not necessarily clear whether LRRK2 facilitates or suppresses the autophagy, and the mechanism of autophagy regulation by LRRK2 remains undefined.

In addition to macroautophagy, LRRK2 has been shown to be associated with the chaperon-mediated autophagy (CMA); whereas LRRK2 serves as a substrate of CMA, binding of PD-associated mutant LRRK2 with lysosomes in the presence of other CMA substrates adversely results in a defective CMA ([@B73]). Taken together with the data related to endocytosis and phagocytosis, LRRK2 appears to function at diverse steps of lytic processes involving lysosomes ([Figure 1](#F1){ref-type="fig"}).

![Possible roles of LRRK2 in endolysosomal trafficking. In endocytic pathways, LRRK2 influences the endosomal trafficking of EGFR as well as lysosomal membrane proteins (LMPs). In phagocytosis in myeloid cells, LRRK2 modulates phagocytic activity via WAVE2 complex or phagosome maturation via PI3K complex and Rubicon. LRRK2 has also been reported to regulate macroautophagy and chaperon-mediated autophagy (CMA). EE, early endosome; LE, late endosome, MVB, multivesicular body; RE, recycling endosome; AP, autophagosome.](fnins-14-00227-g001){#F1}

The Impact of Rab Phosphorylation by LRRK2 {#S4}
==========================================

Since LRRK2 kinase activity is considered as a key in the pathomechanisms of PD, much effort has been devoted to the identification of its substrates. The examples of reported cellular substrates include Endophilin A and ribosomal protein S15 ([@B66]; [@B65]), although further studies are warranted to validate the phosphorylation of these potential substrates. In 2016, [@B91] have reported a subset of Rab GTPases as substrates of LRRK2 in cells. The subsequent and systematic analyses demonstrated that Rab3a-d, Rab5a-c, Rab8a/b, Rab10, Rab12, Rab29 (also known as Rab7L1), Rab35 and Rab43 are phosphorylated by LRRK2 at least upon overexpression ([@B90]). Other groups have also reported that Rab8, Rab10 and Rab29 behave as excellent substrates of LRRK2 in cells ([@B28]; [@B58]; [@B61]). At endogenous levels, LRRK2-mediated phosphorylation likely occurs on Rab3a-d, Rab8a/b, Rab10, Rab12, Rab35 and Rab43 ([@B90]). Phosphorylation site is located in the middle of switch II region of Rab GTPases, *e.g.*, Thr72 in Rab8a, and the structurally equivalent sites in other Rabs, which is predicted to undergo a conformational change upon GTP/GDP binding. Notably, another study have reported that LRRK1, a paralog of LRRK2, phosphorylates Rab7 at Ser72 ([@B33]), suggesting a strong functional connection between LRRK and the Rab family proteins.

Recent advances in the analysis of phosphorylation owes a great deal to the development of Phos-tag SDS-PAGE technique ([@B51]). Researchers no longer need to raise phospho-specific antibodies but can use antibodies against the protein of interest, or even those against the common tags fused to the protein, for western blotting ([@B44]; [@B45]). Because phosphorylation of a subset of Rab GTPases by LRRK2 can easily be detected by their co-expression followed by Phos-tag SDS-PAGE, these Rabs were verified to be excellent substrates of LRRK2 in cells. The phospho-specific antibodies selective for LRRK2-mediated phosphorylation are also being established, such as anti-phospho-Thr73 Rab10 ([@B92]; [@B25]; [@B56]) or anti-phospho-Ser106 Rab12 ([@B92]), and further development of such antibodies is awaited.

A noteworthy finding is that most of the pathogenic LRRK2 mutations commonly and potently enhance its activity to phosphorylate Rab GTPases ([@B91]; [@B28]; [@B58]), leading us to hypothesize that Rab hyperphosphorylation may contribute to the pathogenesis of PD. Recent efforts have thus been focused on the elucidation of the role of phosphorylation of substrate Rabs, especially Rab8 and Rab10, in the physiological and pathological contexts. It has been shown that pathogenic LRRK2 mutations inhibit primary cilia formation that involves Rab8a ([@B90]) and Rab10 ([@B19]), whereas another group has reported that LRRK2 mutations caused centrosomal defects via phosphorylation of Rab8a ([@B61]) and Rab10 ([@B72]) in dividing cells. Overexpression of both wild-type LRRK2 and Rab29 also caused the same defects ([@B62]). Interestingly, centrosomal cohesion and ciliogenesis were both regulated by their phosphorylation-dependent recruitment to their effector, RILPL1 ([@B19]; [@B72]). Considering that ciliogenesis is controlled by centrosome-mediated regulations, these observations likely converge on a single pathway that could be affected by the hyperphosphorylated Rab8/10.

Regarding the effect of Rab phosphorylation on the endolysosomal system, [@B82] have reported that G2019S mutant LRRK2 interferes with endolysosomal trafficking of EGFR by impairing Rab8a function. We have reported that LRRK2-mediated phosphorylation of Rab8 and Rab10 functions to maintain lysosomal homeostasis upon overload stresses ([@B24]). That is, when cells are treated with chloroquine, a lysosomotropic agent that induces lysosomal overload by accumulating within its lumen, LRRK2 and Rab8/10 are targeted onto stressed lysosomes, repress lysosomal swellings and facilitates the extracellular secretion of lysosomal contents. These stress responses are positively regulated by LRRK2-mediated phosphorylation of Rab8/10, via recruiting their effectors EHBP1 and EHBP1L1 onto the overloaded lysosomes. We should note that chloroquine treatment induces the extremely diseased conditions in cells that contain swollen lysosomes with undigested materials; although this is different from healthy state, similar cellular pathology can be observed in aged animals ([@B15]).

The latter finding is different from the rest of above-mentioned observations in two contexts; first, the lysosomal overload is regulated by endogenous wild-type LRRK2, whereas other defects are induced by the pathogenic LRRK2 mutations or by co-overexpression of wild-type LRRK2 with Rab29. This difference may account for the distinct readouts of LRRK2 kinase activity in physiological and pathological conditions, respectively, although the nature of the deleterious effects of the pathogenic mutant LRRK2 on lysosomal overload has not been fully defined. Second, Rab phosphorylation appears to play an inhibitory role in the regulation of centrosomes or endolysosomal EGFR trafficking, whereas the phosphorylation at the same residue plays a promotive role to mitigate the lysosomal overload. These findings are not mutually contradictory; the differences may be explained by the use of different effector proteins (i.e., RILPL1 vs. EHBP1/EHBP1L1) or different subcellular compartment where each Rab is phosphorylated and accumulated (i.e., centrosomes vs. lysosomes).

In addition, there are also intriguing studies reporting the possible readouts of phosphorylation of substrate Rab GTPases by LRRK2, such as the promotion of lipid storage ([@B101]), *trans*-Golgi organization ([@B28]), impaired mitophagy ([@B99]), and α-synuclein propagation ([@B3]). Collectively, the roles and impacts of Rab phosphorylation are being uncovered ([Figure 2](#F2){ref-type="fig"}).

![A "Rab29-LRRK2-Rab8/10 cascade" in the pathobiology of LRRK2. Rab29 on Golgi membranes or overloaded lysosomes recruits and activates LRRK2, which in turn causes LRRK2-mediated phosphorylation and recruitment of Rab8/10 at pricentrosomes/centrosomes or lysosomes. This Rab29-LRRK2-Rab8/10 molecular cascade resulted in the modulation of downstream events, such as centrosomal cohesion, ciliogenesis or lysosome maintenance, via recruiting each effector of Rab8/10. LRRK2 can also phosphorylate Rab29 to regulate *trans*-Golgi organization, and VPS35 mutation results in the activation of LRRK2. Other downstream events include Rab8a-mediated promotion of lipid storage, Rab10-mediated mitophagy regulation and Rab35-mediated promotion of α-synuclein propagation.](fnins-14-00227-g002){#F2}

Relationship Between Rab29 and LRRK2 {#S5}
====================================

In contrast to Rab8 and Rab10 that act downstream of LRRK2, another LRRK2 substrate, Rab29 (Rab7L1), appears to function upstream of LRRK2. *Rab29* was originally highlighted in PD research as a gene located within PD risk locus *PARK16* ([@B85]), and the variants at *PARK16* have been suggested to function coordinately with the common variants at *LRRK2* locus to increase PD risk ([@B60]; [@B76]). Importantly, *Rab29* KO mice share the key histological phenotypes of *Lrrk2* KO mice, in terms of the accumulation of enlarged secondary lysosomes in the kidney proximal tubules ([@B52]). This *in vivo* observation can be explained by our cell-based studies in which Rab29 recruits LRRK2 to the overloaded lysosomes to maintain lysosomal homeostasis ([@B24]). This recruitment by Rab29 is observed at an endogenous level, as knockdown of Rab29 prevented lysosomal localization of endogenous LRRK2. The observation that Rab29 acts upstream of LRRK2 was preceded by other studies showing that Rab29 recruits LRRK2 to the *trans*-Golgi network (TGN) or TGN-derived vesicles ([@B60]; [@B6]) where Rab29 normally resides ([@B36]), and potently upregulates the LRRK2 kinase activity ([@B79]). Following this study, [@B62] have also shown that Rab29 recruits LRRK2 to the Golgi complex and causes centrosomal deficits, although the recruitment of LRRK2 to the Golgi by Rab29 was observed solely under overexpressed conditions. As the above-noted studies commonly showed that the recruitment of LRRK2 by Rab29 in turn results in the recruitment of Rab8 and Rab10 that are phosphorylated by LRRK2, this tandem flow of recruitment may work as the central "Rab29-LRRK2-Rab8/10 cascade" in the LRRK2 pathobiology ([Figure 2](#F2){ref-type="fig"}).

It is not yet clear how Rab29 facilitates the recruitment and activation of LRRK2. Rab29 has been shown to directly bind LRRK2 ([@B60]; [@B6]), and the binding site on LRRK2 has been mapped to the N terminus of LRRK2, such as the ankyrin repeats ([@B79]), armadillo repeats ([@B67]) or HEAT domain that spans these repeats ([@B6]). However, GTP-binding activity of Rab29 is unlikely to affect its interaction with LRRK2, although it should be noted that Rab29 is not likely a typical small GTPase; actually, a Rab29 mutant predicted to mimic the GTP-bound state (Q67N) unexpectedly showed low ability to retain GTP ([@B6]), and that this mutant is diffusely distributed in the cytoplasm upon overexpression ([@B60]; [@B98]). A more recent study has shown that wild-type Rab29 poorly binds the nucleotide, is inefficiently prenylated, and is not bound to a guanine nucleotide dissociation inhibitor (GDI) in the cytosol ([@B30]). Therefore, although LRRK2 functions under the control of Rab29, it functions independently of the classical Rab GTP/GDP switch mechanism and thus behaves differently from typical Rab effectors. Nonetheless, it has also been shown that GTP binding and membrane association of Rab29 are required for its ability to activate LRRK2 as well as the downstream Rab10 recruitment and phosphorylation ([@B30]). Taken together, the Rab29-LRRK2-Rab8/10 cascade is even reminiscent of the so-called "Rab cascade" ([@B75]), although LRRK2 is not likely a guanine nucleotide exchange factor (GEF) of Rab8/10.

To gain more insights into the mechanisms of LRRK2 activation, we should pay more attention to the potent upregulation of LRRK2 kinase activity by the pathogenic mutation in *VPS35* ([@B69]), another causative gene for autosomal-dominant late-onset PD ([@B96]; [@B106]). VPS35 is a major component of the retromer complex that functions at the step of membrane trafficking from early endosomes to *trans*-Golgi, and the dysfunction in this step results in the defective recycling of mannose 6-phosphate receptor (MPR) that delivers lysosomal components into lysosomes. In addition, a prior study has suggested the tripartite functional connection among Rab29, LRRK2 and VPS35 in the intraneuronal membrane trafficking ([@B60]). Thus, it would be interesting to study the detailed relationship between Rab29 and VPS35, both of which regulate LRRK2 kinase activity and lysosomal functions as upstream factors.

It is also unclear how Rab29 phosphorylation by LRRK2 influences the activity of Rab29 to upregulate LRRK2, although it has been reported that a phosphomimetic mutant Rab29, harboring both T71E and S72E, abolished its activity to activate LRRK2 ([@B79]). Two possibilities are considered from this result: first, the T71E/S72E double mutant is not functional; second, Rab29 phosphorylation by LRRK2 acts as a negative feedback to suppress the prolonged activation of LRRK2. Of note, Rab29 phosphorylation at Ser72 may also influence the *trans*-Golgi morphology ([@B28]), prompting us to speculate that the direct and indirect outcomes of Rab29 phosphorylation might be involved in the possible cellular roles.

Relevance to the Disease Mechanisms {#S6}
===================================

The impacts of LRRK2 and its substrate Rab GTPases in the endolysosomal system have also been implicated in the pathomechanism of Parkinson's and related disorders. It has been reported that, in the brains of patients with PD or dementia with Lewy bodies, LRRK2 is abnormally localized to the enlarged granules or vacuoles that correspond to the endolysosomal compartment ([@B39]), although the specificity of the antibodies employed in this study has not been fully validated. Biochemical analysis of post-mortem brain tissues demonstrated that the levels of lysosomal proteins LAMP2a and GBA were significantly reduced in patients with LRRK2 mutations ([@B105]). In fibroblasts from PD patients harboring the LRRK2 G2019S mutation, late endosomes and lysosomes are morphologically altered or disrupted in a LRRK2 kinase activity-dependent manner ([@B32]; [@B41]). One of these studies showed that the dysregulation of lysosome morphology was dependent on an endolysosomal two-pore channel TPC2, which mediates NAADP-induced Ca^2+^ release from acidic organelles ([@B41]). Since other studies have provided evidence of an increased LRRK2 kinase activity in idiopathic PD patients ([@B26]; [@B20]), LRRK2 kinase-mediated dysregulation of the endolysosomes may be a common event in the pathophysiology of PD.

However, the involvement of LRRK2-mediated phosphorylation of Rab GTPases, such as Rab8 or Rab10, and lysosomes in relation PD remains largely unclear. [@B3] have shown that, in cell culture, nematode and rodent models of PD, LRRK2-mediated phosphorylation of Rab35 regulates the propagation of α-synuclein, although they have not systematically analyzed other Rab GTPases involved in this step. They also provided suggestive evidence that the impaired trafficking of α-synuclein to lysosomes may underlie the observed effects. The pathogenic role of Rab35 was also suggested in the previous report showing that the overexpression of Rab35 phosphomutants (T72A, T72D) induced the neurotoxicity in primary cortical neurons and *in vivo* ([@B47]), although we should be cautious about the validity of the use of phosphomutants. Furthermore, another study has reported that the protein level of Rab35 was increased in the substantia nigra of transgenic mice expressing pathogenic LRRK2 (R1441C, G2019S), as well as in the serum samples from PD patients ([@B14]). This study additionally demonstrated that Rab35 overexpression increased the aggregation and secretion of α-synuclein in SH-SY5Y cells. Collectively, it would be plausible to nominate Rab35 as a promising candidate Rab GTPase regulating α-synuclein pathology downstream of LRRK2 ([Figure 2](#F2){ref-type="fig"}).

However, the PD-related pathogenic role of other LRRK2 substrates, such as Rab8 and Rab10, has not been fully clarified. As Rab8/10 phosphorylation participates in the regulation of lysosome morphology and release, it would be reasonable to speculate that hyperphosphorylated Rab8/10 modulates the α-synuclein dynamics (clearance, aggregation or propagation) by affecting the maintenance of lysosomes. Indeed, endolysosomal system has been strongly implicated in the α-synuclein ([@B18]; [@B95]), and it has been shown that endogenous expression of mutant LRRK2 in neurons caused the disruption of lysosomal morphology as well as the increase of α-synuclein insolubility and release via its kinase activity ([@B86]).

Conclusion {#S7}
==========

Ever since LRRK2 has been identified as a major PD gene, much effort has been directed toward unraveling the cellular roles of LRRK2. It is now evident that LRRK2 is a multifaceted protein in a variety of tissues and cells, including immune and nervous systems. Particularly, the altered morphology or function of endolysosomes by LRRK2 are frequently described in the studies using immune-related cells, such as macrophages. In other words, LRRK2-mediated endolysosomal regulation may have critical role(s) in the proper execution of immune and phagocytic responses. For example, LRRK2 has been shown to regulate the efficient clearance of certain pathogens, such as *Listeria monocytogenes*, *Salmonella Typhimurium* and *Mycobacterium tuberculosis* ([@B103]; [@B57]; [@B34]; [@B88]), which may be explained by the altered regulation of phagolysosomes by LRRK2 in the course of innate immune responses. The action of LRRK2 may also cover the adaptive immunity, because antigen presentation by macrophages or dendritic cells is mediated at least in part by the lysosome-related organelle called MHC class II compartment (MIIC), and *LRRK2* has been identified as a risk gene for systemic lupus erythematosus (SLE), a representative autoimmune disorder ([@B104]). Further studies will clarify the most important readout of LRRK2 function and dysfunction around endolysosomes, especially *in vivo*.

Compared with the cellular roles of LRRK2, those of substrate Rab GTPases are yet to be characterized. It is easy to speculate that the phosphorylation of substrate Rab mediates the endolysosomal membrane trafficking downstream of LRRK2, and it would be feasible to assess the contribution of each Rab GTPase. The effect of each phosphorylated Rab on PD pathomechanism would be another big issue to be resolved. Given that Rab phosphorylation is enhanced by pathogenic LRRK2 mutations and that Rab is a critical regulator of membrane transport, it is plausible to hypothesize that the perturbation of intracellular trafficking by hyperphosphorylation of Rab GTPases may eventually cause neurodegeneration.

Based on the above views, pharmaceutical companies are now conducting or planning clinical studies of LRRK2 kinase inhibitors for the treatment or prevention of PD^[1](#footnote1){ref-type="fn"}^. Denali Therapeutics, a leading company developing these inhibitors, has reported that the secretion of a lysosomal lipid bis(monoacylglycerol) phosphate (BMP) into urine and cerebrospinal fluid (CSF) was significantly decreased in humans treated with a LRRK2 inhibitor (source: Denali Therapeutics slide deck^[2](#footnote2){ref-type="fn"}^). This result is consistent with another line of evidence that LRRK2 KO mice and LRRK2 inhibitor-treated monkeys exhibited decreases in urinary BMP ([@B27]), and that urinary BMP was elevated in humans carrying LRRK2 G2019S mutation ([@B1]). These results support the notion that LRRK2 kinase activity contributes to the increased lysosomal secretion, shedding light on the importance of lysosomes in LRRK2 pathobiology. As LRRK2 may be an optimal target for the modification of pathway leading to PD, accelerating the basic research further in various experimental settings and in humans will pave the way toward the establishment of new, cutting-edge strategies to overcome PD.
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